In the US, New Jersey is a life science powerhouse. It’s home to some of the most influential pharma manufacturers in the world. And today, I want to share with you some of the latest developments coming from this hub.
First off, keep your eye on Dr Reddy’s. Most recently, the company extended its strategic partnership with Gland Pharma to launch Ertapenem, which is the generic version of INVANZ.
Before that, in April, Dr Reddy’s also launched a generic for Albendazole tablets, used for the treatment of a variety of parasitic worm infestations. Considering the demand that the Albenza brand and generics received from the US, I expect this to be popular.
Moving on, Wockhard are on the rise – boosted by the growing US markets for scarlet fever and dexamethasone, whilst also producing COVID-19 vaccines in the fight against the global pandemic.
The same goes for Teva Pharmaceuticals – the world’s largest generics maker – which is set for growth following the launch of two new drugs: Huntington’s disease treatment, Austedo; and migraine product, Ajovy.
Finally, there’s Catalent. A company that’s always up to something big and exciting. Recently, Catalent entered a global innovation partnership with HBC to develop a delayed-release formulation of HBC’s OmeGo fish oil.
Go to my profile page for more about myself and my content.
Alongside the growing trend of value-based searches, I wanted to delve into why candidates prioritise companies that focus on fundamental principles and ethics which resonate with them, as opposed to other more material benefits. Find out why, here.
In this episode, Jack speaks with two Co-Founders at Centivax about life as successful entrepreneurs, the journey to acquisition, challenges and learnings - and using them to become an industry-defining author. Listen now.
In this episode, Jack speaks with Twlya Tiongson Neal, Managing Director at Accenture, about commercial strategy and what this really looks like in the current life science landscape. Click to listen.